imd-1041
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00883584)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
IKBKB inhibitor
Prodrug - active metabolite is IMD-0354
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545168 ↗
Also known as
- imd-1041
- imd-1041
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00883584 | Phase 2 | Jul 1, 2008 | Institute of Medicinal Molecular Design, Inc., King Edward VII Hospital, Windsor |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institute of Medicinal Molecular Design, Inc. | For profit | 1 | 1 | 1 | 2008 |
| King Edward VII Hospital, Windsor | Academic/Hospital | 1 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1